IRCT20200105046010N8 IRCT 2020-08-31 Tabriz University of Medical Sciences Ligagliptin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers. In- Vivo Bioequivalence study of Ligagliptin tablets 5mg (ABIDI Pharmaceuticals, Iran) with brand drug (TRAJENTA® 5mg Boehringer Ingelheim, Germany) in Iranian healthy volunteers. 2020-10-05 anticipated 24 Complete https://irct.ir/trial/50362 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: People in different age groups are invited to cooperate through the advertisement.Then people are selected. Individuals will be randomly selected through advertisements. The number of individuals will be randomly selected and the first twelve will be selected as the first sequence and the second twelve will be selected as the second sequence, Blinding description: Candidates are not aware of the test drug or brand name. Bioequivalence In this study the bioquivalence of test and brand of Ligagliptin tablets 5mg will evaluated.. Intervention 1: Intervention group: Single dose of 5 mg Linagliptine tablets (TRAJENTA® 5mg Boehringer Ingelheim, Germany) Pharmaceutical Company as a reference product. Intervention 2: Intervention group 2:Single dose of 5 mg Linagliptine tablet by Abidi Pharmaceutical Company as a test product. No - There is not a plan to make this available Justification or reason for not sharing IPD is These date are as secure between researcher and related industries.